Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

84

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Recruitment

Conditions

Bladder Neoplasm
Neoplasm Recurrence, Local
Transitional Cell, Carcinoma
Carcinoma in Situ
Mycobacterium

Interventions

BIOLOGICAL: EN3348
BIOLOGICAL: Mitomycin C

Sponsor

Bioniche Life Sciences Inc.